Co-Diagnostics Inc (CODX)
Co-Diagnostics, Inc. is a healthcare company focused on molecular diagnostics. It develops, manufactures, and sells reagents for tests that analyze nucleic acid molecules, with products marketed in the United States and internationally. The company’s offerings include the Co-Dx PCR platform, designed for polymerase chain reaction testing in point-of-care and at-home settings, along with PCR diagnostic tests for diseases and conditions such as COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and Zika. Co-Diagnostics also provides multiplexed mosquito-testing products, molecular tools for infectious disease detection, liquid biopsy applications for cancer screening, agricultural testing tools, genetic trait identification in plant and animal genomes, and a portable diagnostic device intended to extend PCR testing beyond traditional laboratory settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CODX
|
$2.69
|
10.1% Upside
|
Fair
|
$45 1,744.3% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-0.2x
|
0.6x
|
12.7x
|
8.924 M
|
2.606 M
|
18.5%
|
96.8%
|
-14.7
|
—
|
59.8%
|
